Single-Cell Genome Sequencing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The single-cell genome sequencing market size was valued at USD 3.82 billion in 2025 and estimated to grow from USD 4.39 billion in 2026 to reach USD 8.8 billion by 2031, at a CAGR of 14.94% during the forecast period (2026-2031). This report is Segmented by Product Type (Reagents & Consumables, and More), Sequencing Technology (Short-Read NGS, Long-Read, and More), Workflow Stage (Single-Cell Isolation & Partitioning, and More), Application (Oncology, and More), End User (Academic & Research Institutes, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Single-Cell Genome Sequencing Market Trends and Insights

Growth in Precision Oncology and MRD Workflows

Minimal residual disease assays now use cell-level variant calling to detect malignant clones at frequencies below 0.01%, a sensitivity that bulk sequencing cannot match. Dana-Farber Cancer Institute and Memorial Sloan Kettering deployed Chromium platforms in 2024 to track clonal evolution in acute lymphoblastic leukemia cohorts, demonstrating clinical utility. FDA approval of a supplemental Oncomine Dx panel in October 2024 legitimized single-cell data in companion diagnostics, accelerating payer reimbursement and pharmaceutical trial adoption. Early MRD detection cuts relapse-associated costs and compresses oncology drug-development timelines, reinforcing spending momentum within the single cell genome sequencing market.

Advances in Single-Cell WGA Chemistry Improving Data Quality

Allelic dropout and GC bias historically limited clinical translation. Takara Bio’s 2024 PicoPLEX update achieved over 95% genome coverage at 30× depth, narrowing the fidelity gap with bulk methods. BioSkryb’s primary-template-directed amplification reduced false structural calls by 60% versus legacy MDA kits. Regulators now reference uniformity metrics in submissions, favoring suppliers that document low-bias chemistries, and further fueling the single cell genome sequencing market.

High Per-Sample and Instrument Costs

Per-sample outlays range from USD 500 to USD 2,000, while flagship sequencers list at USD 1 million, deterring smaller centers. Consumables remain pricey because of proprietary cartridge designs, and cloud bioinformatics adds USD 50 to USD 150 per sample. Cost remains a short-term drag on the single cell genome sequencing market.

Other drivers and restraints analyzed in the detailed report include:

• Declining Sequencing Costs and Availability of High-Throughput Platforms
• Expansion of Cell-Atlas and Biobank Initiatives
• Complex Bioinformatics and Storage Burden

Segment Analysis

Reagents and consumables captured 44.78% of 2025 revenue, underscoring their recurring nature within the single cell genome sequencing market size context. Proprietary microfluidic cartridges tie every experiment to vendor-specific kits, creating predictable reorder cycles even as instrument placements mature. Instruments are projected to grow at 16.89% CAGR because benchtop long-read systems, like the USD 169,000 Vega, allow mid-cap institutes to buy rather than schedule core-facility time.

Install-base expansion sets a replacement wave in motion, especially in North America where early NovaSeq units near depreciation. Universal library kits from Takara Bio and QIAGEN aim to loosen consumable lock-in, but integrated vendors defend share through lease financing and bundled reagents. Software subscriptions monetize bioinformatics through per-sample fees instead of perpetual licenses, aligning revenue with throughput and supporting long-term cash flow visibility across the single cell genome sequencing market.

Short-read platforms held 66.90% share of the single cell genome sequencing market in 2025 on the back of NovaSeq and NextSeq economies. Long-read growth at 17.88% CAGR is fueled by structural-variant detection and haplotype phasing prowess, which short reads cannot match without complex assemblies.

Oxford Nanopore’s PromethION Plus promises sub-USD 345 genomes, while targeted capture methods eliminate whole-genome amplification, improving data fidelity for prenatal genetics and oncology. Regulatory frameworks still evolve for long reads, yet early clinical validations suggest escalating displacement potential within the single cell genome sequencing industry.

Complete Report Scope:

• By Product Type
  • Reagents & Consumables
  • Instruments
  • Software & Services
• By Sequencing Technology / Platform
  • Short-read NGS
  • Long-read
  • PCR
  • Microarray
  • Other enabling technologies
• By Workflow Stage
  • Single-cell isolation & partitioning
  • Whole genome amplification (WGA) & library preparation
  • Genomic analysis & data interpretation
• By Application
  • Oncology
  • Immunology & Infectious Disease
  • Prenatal/Embryo Genetics & Reproductive Health
  • Neurology & Somatic Mosaicism
  • Microbiology & Metagenomics
• By End User
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & diagnostic laboratories
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 43.70% of revenue in 2025, benefiting from NIH funding and the earliest clinical MRD implementations. The U.S. FDA’s October 2024 approval of single-cell variant calling within Oncomine Dx validated the technology for diagnostics and stimulated hospital procurement. Export controls risk parts shortages, but local manufacturing depth mitigates severe disruption.

Europe leverages cross-border consortia like Human Cell Atlas to share reference datasets, although GDPR hinders economical cloud storage. Spatial-omics adoption at Amsterdam UMC and Charité underscores innovation, yet on-premises compute investment slows roll-out.

Asia-Pacific is the fastest-growing territory at 16.72% CAGR, propelled by Chinese provincial precision-medicine budgets and Japanese pharma embedding single-cell QC in cell-therapy lines. Entity-List restrictions challenge Chinese buyers, motivating accelerated domestic instrument development by MGI Tech.

Middle East and Africa rely on sovereign wealth funding in Gulf states for genomics centers, while Latin American growth remains currency-sensitive. Brazil’s national biobank integrated single-cell protocols in 2024, future-proofing sample assets and broadening regional access to the single cell genome sequencing market.

List of Companies Covered in this Report:

• Agilent Technologies
• BGI Americas
• BGI
• Bio-Rad Laboratories
• BioSkryb Genomics
• CD Genomics
• Danaher
• Roche
• Illumina
• MGI Tech
• Mission Bio
• Novogene
• Oxford Nanopore Technologies
• PacBio (Pacific Biosciences)
• Psomagen
• QIAGEN
• Silicon Biosystems (Ampli1)
• Standard BioTools (Fluidigm)
• Takara Bio
• Thermo Fisher Scientific
• Yikon Genomics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support